{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:32:02Z","timestamp":1790299922644,"version":"4.1.0"},"reference-count":0,"publisher":"American Diabetes Association","issue":"1","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2000,1,1]]},"abstract":"<jats:p>OBJECTIVE: We tested whether oral hypoglycemic agents (OHA), gliclazide with or without metformin, during an isoenergetic (ISO) and then a low-energy diet (LED) improve the altered kinetics of whole-body protein metabolism in type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 13 type 2 diabetic patients (aged 51+\/-2 years, weight 110+\/-5 kg, BMI 41+\/-1 kg\/m2, fasting glucose [FSG] 11.5+\/-0.9 mmol\/l) (means+\/-SEM) and 10 obese control subjects (48+\/-3 years, 98+\/-6 kg, 37+\/-2 kg\/m2, FSG 5.5+\/-0.3 mmol\/l) consumed an ISO, 1.5 g x kg(-1) x day(-1) protein for a body weight corresponding to a BMI of 25 (BMI25), a formula diet (7 days for obese control subjects, 15 days for diabetic patients), and then a 28-day LED with 50% of the energy of ISO but the same protein intake (101+\/-2 g\/day). OHAs were given during ISO (days 8-15) and LED. On days 6-8 (and 12-14 for diabetic subjects) of ISO and 26-28 of LED, the 60-h oral 15N-glycine method was used to obtain nitrogen flux (Q), synthesis (S), and breakdown (B). Muscle protein catabolism was estimated from N(tau)-methylhistidine (3MH) excretion. RESULTS: During ISO with hyperglycemia, Q, and B adjusted for fat-free mass, sex, and age were higher and nitrogen balance and net endogenous protein synthesis (S-B) lower than in control subjects (P&amp;lt;0.05). OHA decreased FSG (9+\/-1 mmol\/l) and 3MH and increased plasma insulin-to-glucose ratio, nitrogen retention, and S-B to levels in control subjects. The change in S-B correlated with that in FSG (r = -0.845, P = 0.001) and in fasting plasma C-peptide (r = 0.852, P = 0.0005). With LED and OHA, weight decreased 6.3 kg, glycemia reached near-normal levels, and nitrogen equilibrium was maintained; Q decreased by 7%, S and B by 11% (P&amp;lt;0.05) to values found in control subjects. CONCLUSIONS: OHA during ISO corrected protein turnover in relation to glycemia and plasma C-peptide. The LED maintained protein homeostasis in obese control subjects and, in diabetes patients with OHA, normalized protein metabolism. These findings have implications for diet and OHA prescription.<\/jats:p>","DOI":"10.2337\/diacare.23.1.1","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":101,"title":["Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes."],"prefix":"10.2337","volume":"23","author":[{"given":"R","family":"Gougeon","sequence":"first","affiliation":[{"name":"McGill Nutrition and Food Science Center, Royal Victoria Hospital, Montr\u00e9al, Qu\u00e9bec, Canada. rgougeon@rvhmed.lan.mcgill.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Styhler","sequence":"additional","affiliation":[{"name":"McGill Nutrition and Food Science Center, Royal Victoria Hospital, Montr\u00e9al, Qu\u00e9bec, Canada. rgougeon@rvhmed.lan.mcgill.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Morais","sequence":"additional","affiliation":[{"name":"McGill Nutrition and Food Science Center, Royal Victoria Hospital, Montr\u00e9al, Qu\u00e9bec, Canada. rgougeon@rvhmed.lan.mcgill.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"Jones","sequence":"additional","affiliation":[{"name":"McGill Nutrition and Food Science Center, Royal Victoria Hospital, Montr\u00e9al, Qu\u00e9bec, Canada. rgougeon@rvhmed.lan.mcgill.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E B","family":"Marliss","sequence":"additional","affiliation":[{"name":"McGill Nutrition and Food Science Center, Royal Victoria Hospital, Montr\u00e9al, Qu\u00e9bec, Canada. rgougeon@rvhmed.lan.mcgill.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/23\/1\/1\/449577\/10857959.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/23\/1\/1\/449577\/10857959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T14:07:11Z","timestamp":1647094031000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/23\/1\/1\/21132\/Effects-of-oral-hypoglycemic-agents-and-diet-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.23.1.1","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1,1]]}}}